Biotechnology

Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)

BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin ...

2021-10-14 20:46 3869

Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with Its AI Immunology Platforms

The company's PIONEER™, EDEN™, and RAVEN™ platforms mimic the human immune system to simplify the drug development process for a range of diseases LONDON, Oct. 14, 2021 /PRNewswire/ -- Based on its recent analysis of the European AI-enabled drug discovery market,Frost & Sullivan recognizes Evaxio...

2021-10-14 19:30 2176

BioAgilytix Closes Acquisition of Australia-based 360biolabs®

Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages DURHAM, N.C., Oct. 14, 2021 /...

2021-10-14 19:00 2007

One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows

* The vaccine is more than 75% effective among subjects under the age of 60. Sputnik Light also provides much higher efficacy against severe disease and hospitalizations.  * Sputnik Light has demonstrated a superior efficacy compared with some two-shot vaccines, which have shown a major decli...

2021-10-13 20:30 5649

Gilead Sciences Partners with the International AIDS Society to Champion Stigma-free HIV Care Services in Asia and Latin America

SINGAPORE, Oct. 13, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced its partnership with IAS - the International AIDS Society - to expand theMe & My Healthcare Provider campaign  to three loca...

2021-10-13 13:00 2053

Vitality International - Pioneering Algorithm Calculates The Number Of Years Individuals Can Expect To Live In Good Health

- Research shows number of years people are spending in ill health is increasing, due to the rising prevalence of chronic diseases, driven by unhealthy lifestyles - Experts call for focus on healthspan, the quality of life, alongside lifespan, the quantity of life, citing significant economic an...

2021-10-12 22:54 3005

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

* Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors * Investment serves customers in addressing larger patient populations with new curative treatments * Enables suspension production of viral vectors up to...

2021-10-12 21:00 4117

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine

Agreement Expands on the Companies' Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle ce...

2021-10-12 20:23 2952

Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins

FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produc...

2021-10-12 10:30 3349

Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021 by American Association for the Study of Liver Diseases

HANGZHOU and SHAOXING, China, Oct. 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the results of Phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) will be presented in oral parallel session...

2021-10-12 08:30 4320

Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline

HANGZHOU, China and SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the closing of an$70 million Series C financing. The f...

2021-10-12 08:00 4445

Twist Alliance Pan-Cancer Methylation Panel Global Launch Event - A Strategic Collaboration Between AnchorDx and Twist Bioscience for Pan-Cancer Liquid Biopsy

GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and targeted enrichment for next-generation sequencing (NGS), was launched globally onSeptember 24th (U...

2021-10-11 21:00 4362

Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China

WOBURN, Mass., Oct. 11, 2021 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIRT) using SIR-Spheres®Y-90 resin microspheres in China was successfully performed ...

2021-10-11 20:00 2870

Sai Life Sciences presents mid-term report on Sai Nxt initiative; reveals upsurge in capabilities

- Completes two-thirds of its investment target of US$150M - Demonstrates a leap forward in capabilities across all focus areas – People, Processes, and Infrastructure HYDERABAD, India, Oct. 11, 2021 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development and Manufac...

2021-10-11 16:50 4134

18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR™ Presented as Late Breaking Trial at VIVA

GENEVA, Oct. 11, 2021 /PRNewswire/ -- 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance's n...

2021-10-11 08:00 1203

Sequential Skin raise US $1.65M in oversubscribed seed round to revolutionise skin health with their novel skin microbiome testing kit

LONDON, Oct. 11, 2021 /PRNewswire/ -- Sequential Skin Ltd , a UK/Singapore biotech start-up has raised US $1.65M in its oversubscribed seed round – to revolutionise the future of skin health.

2021-10-11 06:00 3504

Breakthrough for medtech pioneer: Syntellix receives product approval for India, opening up fast-growing market with 1.38 billion people

Syntellix CEO Claassen: "Greatest and most important success in the company's history" - Indian CDSCO grants approvals for five MAGNEZIX® product families - The Era of Magnesium for orthopaedics and traumatology now also begins in India - Subcontinent will be the world's most populous growth m...

2021-10-07 22:08 2881

Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-driven Cancers

HOUSTON and SINGAPORE, Oct. 7, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the presentation of pre-clinical data on novel biomarkers for HER3-driven cancers at the...

2021-10-07 21:03 2214

Deep Longevity Launches Longevity Medicine Course for Physicians with Industry Experts

HONG KONG, Oct. 7, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK)'s Deep Longevity, Inc, a company acquired on14 December 2020 which develops artificial intelligence to track human aging and ...

2021-10-07 15:30 11678

Research on Using Fluid Biomarkers to Advance Drug Treatments and Therapies for Alzheimer's, Traumatic Brain Injury, Concussion, and Other Neurodegenerative Diseases Presented at World Congress of Neurology 2021 by Neuroscientist Henrik Zetterberg

LONDON, Oct. 7, 2021 /PRNewswire/ -- New developments in the field of blood biomarkers for brain diseases including traumatic brain injury (TBI), and neurodegenerative diseases such as Alzheimer's, were unveiled during three lectures at the 25th BiennialWorld Congress of Neurology, October 3–7, 2...

2021-10-07 12:02 2431
1 ... 166167168169170171172 ... 185

Week's Top Stories